Results 171 to 180 of about 26,203 (316)

Experiencia clínica del tratamiento con onabotulinumtoxin A en pacientes con migraña refractaria [PDF]

, 2012
To analyse our experience in the treatment of refractory chronic migraine, episodic frequent refractory migraine (>= 10 days/month), with onabotulinumtoxin A (OnabotA). PATIENTS AND METHODS.
Fernandez-Torron, R. (Roberto), Irimia, P. (Pablo), Luquin, M.R. (María Rosario), Martinez-Vila, E. (Eduardo), Ortega-Cubero, S. (Sara), Palma, J.A. (José Alberto), Riverol, M. (Mario)   +6 more
core  

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine

, 2021
Hisaka Igarashi, Mamoru Shibata, Akichika Ozeki, Kathleen A. Day, Taka Matsumura   +4 more
openalex   +2 more sources

Pre‐natal nutrition as risk factor for painful temporomandibular disorders and headaches in young adults

Headache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 29-39, January 2026.
Abstract Objective To investigate the relationship between prenatal nutrition and the development of painful temporomandibular disorders (p‐TMD) and headaches in offspring during young adulthood. Background p‐TMD are a common source of chronic orofacial pain and are often comorbid with headaches.
Cristina Rocha Exposto, Mojdeh Mansoori, Bodil Hammer Bech, Anne Ahrendt Bjerregaard, Sjurdur Frodi Olsen, Lene Baad‐Hansen   +5 more
wiley   +1 more source

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

Headache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 336-340, January 2026.
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão, Filipa Dourado Sotero, Linda Azevedo Kauppila, Isabel Pavão Martins   +3 more
wiley   +1 more source

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 202-212, January 2026.
Abstract Objective To evaluate pharmacokinetics (PK), safety, and tolerability of a weight‐adjusted dose of rimegepant orally disintegrating tablet (ODT) in children (aged ≥6 to <12 years) with a history of migraine. Background Rimegepant 75 mg ODT is approved for acute treatment of migraine (with or without aura) and preventive treatment of episodic ...
Chay Ngee Lim, Gary Mo, Rajinder Bhardwaj, Craig M. Comisar, Beth L. Emerson, Kyle T. Matschke, Ogert Fisniku, Richard Bertz, Robert Croop, Jing Liu   +9 more
wiley   +1 more source

Hot spots and labyrinths: Why neuromodulation devices for episodic migraine should be personalized

, 2014
Markus A. Dahlem, Bernd Schmidt, Ingo Bojak, Sebastian Daniel Boie, Frederike Kneer, Nouchine Hadjikhani, Jürgen Kurths   +6 more
openalex   +1 more source

Persistent postural‐perceptual dizziness versus vestibular migraine: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 298-306, January 2026.
Abstract Objective This article reviews the differences and similarities between persistent postural‐perceptual dizziness (PPPD) and vestibular migraine. Background PPPD is considered a chronic functional vestibular disorder characterized by persistent dizziness, unsteadiness, nonspinning vertigo, and often exacerbated by upright posture, movement, or ...
David Moreno‐Ajona
wiley   +1 more source

Psychological adjustment in children with episodic migraine: A population-based study.

, 2014
Marco A. Arruda, Renato Arruda
openalex   +1 more source

Quality of life changes in cluster headache: Convergent validity, responsiveness, and interpretability of the Cluster Headache Quality of Life scale as a patient‐reported outcome measure

Headache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 213-229, January 2026.
Abstract Objective Cluster headache (CH) significantly impacts patients' quality of life (QoL). We aim to validate the Cluster Headache Quality of Life scale (CHQ) for measuring QoL changes in patients with CH. Methods In this multicenter, prospective, longitudinal psychometric validation study, participants, all with chronic CH (CCH), completed the ...
Willemijn C. Naber, Paulien J. van Tilborg, Roemer B. Brandt, Julia J. Jansen, Leopoldine A. Wilbrink, Wim M. Mulleners, Erkan Kurt, Willemijn Leen, Frank J. P. M. Huygen, Denise Bijlenga, Rolf Fronczek   +10 more
wiley   +1 more source

Gepants for headache prevention in children and adolescents: A multicenter chart review study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 239-248, January 2026.
Abstract Introduction There is an unmet need for safe, evidence‐based pharmacologic treatments for migraine prevention in children and adolescents. Rimegepant and atogepant, calcitonin gene‐related peptide receptor antagonists (gepants), have been shown to be efficacious and well‐tolerated preventive treatments in adults with migraine.
Lauren Shin, Olivia Mentz, Amy A. Gelfand, Blanca Marquez de Prado, Hannah Shapiro, Ann Oh, Ogo‐Oluwa Onifade, Jessica Saunders, Nichelle Raj, Christina L. Szperka   +9 more
wiley   +1 more source